Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluorometholone

FDA-approved product (cream, topical), marketed as Fluor-Op, Fluorometholone, Fml and 2 more.

Registered studies
37
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Fluorometholone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Eye inflammation
  • Hemorrhoid
  • Inflammation

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids; Corticosteroids, moderately potent (group ii); Corticosteroids, moderately potent, other combinations; Corticosteroids, combinations for treatment of acne; Corticosteroids, plain
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis34.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

37registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluorometholone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluorometholone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Dextenza Compared to Topical Fluorometholone in Patients With Ocular Rosacea

    NCT04839549 · start 2020-06-06

    Registered record
    Registry ID
    NCT04839549
    Conditions
    Ocular Rosacea
    Interventions
    Dextenza 0.4Mg Ophthalmic Insert; Fluoromethalone .01%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2020-06-06
    Completion
    2022-11-29
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Rosacea
    InterventionDextenza 0.4Mg Ophthalmic Insert; Fluoromethalone .01%
    PhasePhase 4
    Registry statusWithdrawn

  • Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA)

    NCT04117698 · start 2019-11-01

    Registered record
    Registry ID
    NCT04117698
    Conditions
    Uveitis, Anterior
    Interventions
    Antitubercular treatment (RIFATER ©); Ethambutol; RIFINAH ©
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-11-01
    Completion
    2023-05-01
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUveitis, Anterior
    InterventionAntitubercular treatment (RIFATER ©); Ethambutol; RIFINAH ©
    PhasePhase 3
    Registry statusUnknown

  • Ocular Micro-vascular Research Base on Functional Slip Lamp Biomicroscopy

    NCT03747614 · start 2017-06-30

    Registered record
    Registry ID
    NCT03747614
    Conditions
    Dry Eye Syndromes; Inflammation; Microvessels
    Interventions
    Fluorometholone; Functional Slit-Lamp Biomicroscopy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-06-30
    Completion
    2020-06-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Syndromes; Inflammation; Microvessels
    InterventionFluorometholone; Functional Slit-Lamp Biomicroscopy
    PhasePhase 4
    Registry statusUnknown

  • Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis

    NCT04376970 · start 2017-04-01

    Registered record
    Registry ID
    NCT04376970
    Conditions
    Adenoviral Keratoconjunctivitis
    Interventions
    FLUCON®; Cyclosporine A eye drops 0.5%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-04-01
    Completion
    2019-04-01
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenoviral Keratoconjunctivitis
    InterventionFLUCON®; Cyclosporine A eye drops 0.5%
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy of Lotemax Versus FML in Subjects Undergoing PRK for the Correction of Mild to Moderate Myopia, 3- Month Follow-up Study

    NCT02974387 · start 2017-04

    Registered record
    Registry ID
    NCT02974387
    Conditions
    Must be PRK Candidate
    Interventions
    Fluorometholone(FML); Loteprednol (Lotemax)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-04
    Completion
    2017-11
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMust be PRK Candidate
    InterventionFluorometholone(FML); Loteprednol (Lotemax)
    PhasePhase 4
    Registry statusUnknown

  • Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery

    NCT02816905 · start 2015-10

    Registered record
    Registry ID
    NCT02816905
    Conditions
    Intraocular Pressure
    Interventions
    0.1 % Dexamethasone; 0.1% Fluorometholone; 1% Rimexolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-10
    Completion
    2016-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntraocular Pressure
    Intervention0.1 % Dexamethasone; 0.1% Fluorometholone; 1% Rimexolone
    PhasePhase 4
    Registry statusCompleted

  • Loteprednol vs. Prednisolone and Fluorometholone

    NCT03123614 · start 2014-09-19

    Registered record
    Registry ID
    NCT03123614
    Conditions
    Intraocular Pressure; Corneal Opacity
    Interventions
    Loteprednol Etabonate 0.5% Oph Gel; Prednisolone Acetate 1% Oph Susp
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-09-19
    Completion
    2018-07
    Enrolment
    131

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntraocular Pressure; Corneal Opacity
    InterventionLoteprednol Etabonate 0.5% Oph Gel; Prednisolone Acetate 1% Oph Susp
    PhasePhase 4
    Registry statusCompleted

  • Topical Steroid Treatment For Dry Eye

    NCT02218827 · start 2014-09

    Registered record
    Registry ID
    NCT02218827
    Conditions
    Dry Eye
    Interventions
    Loteprednol Etabonate (FML)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2014-09
    Completion
    2015-09
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionLoteprednol Etabonate (FML)
    PhaseNot applicable
    Registry statusUnknown

  • The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements

    NCT02030990 · start 2014-08

    Registered record
    Registry ID
    NCT02030990
    Conditions
    Corneal Opacity
    Interventions
    Mitomycin-C; Fluorometholone 1% topical ocular steroid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2014-08
    Completion
    2023-07
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Opacity
    InterventionMitomycin-C; Fluorometholone 1% topical ocular steroid
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)

    NCT02051023 · start 2014-02

    Registered record
    Registry ID
    NCT02051023
    Conditions
    Dry Eye
    Interventions
    FML 0.1% eyedrops; Liquifilm artificial tears eyedrops
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-02
    Completion
    2014-12
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionFML 0.1% eyedrops; Liquifilm artificial tears eyedrops
    PhasePhase 3
    Registry statusCompleted

  • Fluorometholone as Ancillary Therapy for TT Surgery

    NCT01949454 · start 2013-11

    Registered record
    Registry ID
    NCT01949454
    Conditions
    Trichiasis; Trachoma; Bilamellar Tarsal Rotation
    Interventions
    Fluorometholone 0.1% ophthalmic solution; Artificial tears (Placebo)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-11
    Completion
    2016-04
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTrichiasis; Trachoma; Bilamellar Tarsal Rotation
    InterventionFluorometholone 0.1% ophthalmic solution; Artificial tears (Placebo)
    PhaseNot applicable
    Registry statusCompleted

  • A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome

    NCT02011776 · start 2013-03

    Registered record
    Registry ID
    NCT02011776
    Conditions
    Dry Eye Syndromes; Sjögren Syndrome
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-03
    Completion
    2013-11
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Syndromes; Sjögren Syndrome
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Evaluation of Therapeutic Effect of Bandage Contact Lenses ( BCL) on Dry Eye Caused by Sjogren's Syndrome

    NCT02147509 · start 2013-03

    Registered record
    Registry ID
    NCT02147509
    Conditions
    Sjögren's Syndrome Patients With Severe Dry Eye
    Interventions
    0.02% Fm, SH; 0.02% Fm, SH, 0.05% CsA; 0.02% Fm, SH, tBCL; 0.02% Fm, SH, AS
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-03
    Completion
    2014-04
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSjögren's Syndrome Patients With Severe Dry Eye
    Intervention0.02% Fm, SH; 0.02% Fm, SH, 0.05% CsA; 0.02% Fm, SH, tBCL; 0.02% Fm, SH, AS
    PhaseNot applicable
    Registry statusCompleted

  • Topical Steroid Treatment After Posterior Lamellar Corneal Transplantation

    NCT01682421 · start 2012-09

    Registered record
    Registry ID
    NCT01682421
    Conditions
    Endothelial Dystrophy; Secondary Bullous Keratopathy; Posterior Lamellar Keratoplasty; Descemet's Stripping Endothelial Keratoplasty
    Interventions
    Weak steroid (Flurolon, Allergan); Potent steroid (Maxidex, Alcon)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2012-09
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndothelial Dystrophy; Secondary Bullous Keratopathy; Posterior Lamellar Keratoplasty; Descemet's Stripping Endothelial Keratoplasty
    InterventionWeak steroid (Flurolon, Allergan); Potent steroid (Maxidex, Alcon)
    PhaseNot applicable
    Registry statusWithdrawn

  • Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease

    NCT01562795 · start 2012-03

    Registered record
    Registry ID
    NCT01562795
    Conditions
    Moderate to Severe Dry Eye Syndrome
    Interventions
    nonsteroid anti-inflammatory drops; nonsteroid anti-inflammatory drops; corticosteroids; artificial tear substitute
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-03
    Completion
    2012-07
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate to Severe Dry Eye Syndrome
    Interventionnonsteroid anti-inflammatory drops; nonsteroid anti-inflammatory drops; corticosteroids; artificial tear substitute
    PhaseNot applicable
    Registry statusCompleted